Published in Biochemistry on October 07, 2011
Biochemical characterization of highly purified leucine-rich repeat kinases 1 and 2 demonstrates formation of homodimers. PLoS One (2012) 1.09
LRRK2 pathobiology in Parkinson's disease. J Neurochem (2014) 0.97
LRRK2: cause, risk, and mechanism. J Parkinsons Dis (2013) 0.88
Current understanding of LRRK2 in Parkinson's disease: biochemical and structural features and inhibitor design. Future Med Chem (2012) 0.86
The Parkinson disease-linked LRRK2 protein mutation I2020T stabilizes an active state conformation leading to increased kinase activity. J Biol Chem (2014) 0.82
Unique functional and structural properties of the LRRK2 protein ATP-binding pocket. J Biol Chem (2014) 0.81
Type II kinase inhibitors show an unexpected inhibition mode against Parkinson's disease-linked LRRK2 mutant G2019S. Biochemistry (2013) 0.79
Altered Development of Synapse Structure and Function in Striatum Caused by Parkinson's Disease-Linked LRRK2-G2019S Mutation. J Neurosci (2016) 0.79
LRRK2 GTPase dysfunction in the pathogenesis of Parkinson's disease. Biochem Soc Trans (2012) 0.78
Rare variants analysis of cutaneous malignant melanoma genes in Parkinson's disease. Neurobiol Aging (2016) 0.75
WHAT IF: a molecular modeling and drug design program. J Mol Graph (1990) 24.35
SFCHECK: a unified set of procedures for evaluating the quality of macromolecular structure-factor data and their agreement with the atomic model. Acta Crystallogr D Biol Crystallogr (1999) 19.57
Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J Med Chem (2004) 15.51
Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron (2004) 14.35
Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron (2004) 13.99
Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. J Med Chem (2004) 7.96
Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc Natl Acad Sci U S A (2005) 6.98
Protein structure modeling with MODELLER. Methods Mol Biol (2008) 6.28
Kinase activity is required for the toxic effects of mutant LRRK2/dardarin. Neurobiol Dis (2006) 5.96
Molecular pathophysiology of Parkinson's disease. Annu Rev Neurosci (2005) 5.93
Kinase activity of mutant LRRK2 mediates neuronal toxicity. Nat Neurosci (2006) 5.32
Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity. Hum Mol Genet (2007) 4.99
Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's disease. Nat Med (2010) 4.45
Surface comparison of active and inactive protein kinases identifies a conserved activation mechanism. Proc Natl Acad Sci U S A (2006) 4.09
Phosphorylation of 4E-BP by LRRK2 affects the maintenance of dopaminergic neurons in Drosophila. EMBO J (2008) 3.51
Solvent isotope effects of enzyme systems. Methods Enzymol (1982) 3.01
14-3-3 binding to LRRK2 is disrupted by multiple Parkinson's disease-associated mutations and regulates cytoplasmic localization. Biochem J (2010) 2.82
GTP binding is essential to the protein kinase activity of LRRK2, a causative gene product for familial Parkinson's disease. Biochemistry (2007) 2.71
A helix scaffold for the assembly of active protein kinases. Proc Natl Acad Sci U S A (2008) 2.51
Phosphorylation of ezrin/radixin/moesin proteins by LRRK2 promotes the rearrangement of actin cytoskeleton in neuronal morphogenesis. J Neurosci (2009) 2.36
Substrate specificity and inhibitors of LRRK2, a protein kinase mutated in Parkinson's disease. Biochem J (2009) 2.33
Did protein kinase regulatory mechanisms evolve through elaboration of a simple structural component? J Mol Biol (2005) 2.28
The Parkinson's disease-associated protein, leucine-rich repeat kinase 2 (LRRK2), is an authentic GTPase that stimulates kinase activity. Exp Cell Res (2007) 2.27
LRRK2 mutations in Parkinson disease. Neurology (2005) 2.01
Leucine-rich repeat kinase 2 phosphorylates brain tubulin-beta isoforms and modulates microtubule stability--a point of convergence in parkinsonian neurodegeneration? J Neurochem (2009) 1.91
Type and frequency of mutations in the LRRK2 gene in familial and sporadic Parkinson's disease*. Brain (2005) 1.85
The Parkinson disease-associated protein kinase LRRK2 exhibits MAPKKK activity and phosphorylates MKK3/6 and MKK4/7, in vitro. J Neurochem (2009) 1.71
The proton inventory technique. CRC Crit Rev Biochem (1984) 1.64
GTPase activity plays a key role in the pathobiology of LRRK2. PLoS Genet (2010) 1.63
Role of the glycine triad in the ATP-binding site of cAMP-dependent protein kinase. J Biol Chem (1997) 1.55
Low-barrier hydrogen bonds and low fractionation factor bases in enzymatic reactions. Biochemistry (1992) 1.49
MKK6 binds and regulates expression of Parkinson's disease-related protein LRRK2. J Neurochem (2010) 1.28
Kinetic mechanistic studies of wild-type leucine-rich repeat kinase 2: characterization of the kinase and GTPase activities. Biochemistry (2010) 1.17
Mechanism of enolase: the crystal structure of enolase-Mg2(+)-2-phosphoglycerate/phosphoenolpyruvate complex at 2.2-A resolution. Biochemistry (1991) 0.94
Development of a mechanism-based high-throughput screen assay for leucine-rich repeat kinase 2--discovery of LRRK2 inhibitors. Anal Biochem (2010) 0.86
Clinical traits of LRRK2-associated Parkinson's disease in Ireland: a link between familial and idiopathic PD. Parkinsonism Relat Disord (2005) 0.80
A probability-based approach for high-throughput protein phosphorylation analysis and site localization. Nat Biotechnol (2006) 12.13
Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury. Nat Chem Biol (2005) 11.63
Identification of RIP1 kinase as a specific cellular target of necrostatins. Nat Chem Biol (2008) 9.24
Large-scale phosphorylation analysis of mouse liver. Proc Natl Acad Sci U S A (2007) 6.08
Two RNAi complexes, RITS and RDRC, physically interact and localize to noncoding centromeric RNAs. Cell (2004) 4.34
Optimization and use of peptide mass measurement accuracy in shotgun proteomics. Mol Cell Proteomics (2006) 4.25
BMP type I receptor inhibition reduces heterotopic [corrected] ossification. Nat Med (2008) 4.20
Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor. J Immunol (2005) 4.18
The absolute quantification strategy: a general procedure for the quantification of proteins and post-translational modifications. Methods (2005) 3.71
Large-scale phosphorylation analysis of alpha-factor-arrested Saccharomyces cerevisiae. J Proteome Res (2007) 3.13
Dicer-dependent endothelial microRNAs are necessary for postnatal angiogenesis. Proc Natl Acad Sci U S A (2008) 3.03
Steps in assembly of silent chromatin in yeast: Sir3-independent binding of a Sir2/Sir4 complex to silencers and role for Sir2-dependent deacetylation. Mol Cell Biol (2002) 2.93
A proteomic strategy for gaining insights into protein sumoylation in yeast. Mol Cell Proteomics (2004) 2.58
Quantitative phosphoproteomics identifies substrates and functional modules of Aurora and Polo-like kinase activities in mitotic cells. Sci Signal (2011) 2.33
Quantitative phosphorylation profiling of the ERK/p90 ribosomal S6 kinase-signaling cassette and its targets, the tuberous sclerosis tumor suppressors. Proc Natl Acad Sci U S A (2005) 2.23
The impact of peptide abundance and dynamic range on stable-isotope-based quantitative proteomic analyses. J Proteome Res (2008) 2.11
Acid β-glucosidase mutants linked to Gaucher disease, Parkinson disease, and Lewy body dementia alter α-synuclein processing. Ann Neurol (2011) 2.11
Pharmacologic inhibition of the anaphase-promoting complex induces a spindle checkpoint-dependent mitotic arrest in the absence of spindle damage. Cancer Cell (2010) 2.08
Necrostatin-1 reduces histopathology and improves functional outcome after controlled cortical impact in mice. J Cereb Blood Flow Metab (2008) 2.06
Radiation-induced IFN-gamma production within the tumor microenvironment influences antitumor immunity. J Immunol (2008) 1.93
Structural genomics: a pipeline for providing structures for the biologist. Protein Sci (2002) 1.91
Necroptosis, a novel form of caspase-independent cell death, contributes to neuronal damage in a retinal ischemia-reperfusion injury model. J Neurosci Res (2010) 1.89
Discovery of inhibitors that elucidate the role of UCH-L1 activity in the H1299 lung cancer cell line. Chem Biol (2003) 1.85
Enhanced analysis of metastatic prostate cancer using stable isotopes and high mass accuracy instrumentation. J Proteome Res (2006) 1.82
Quantitative proteomics reveals a dynamic interactome and phase-specific phosphorylation in the Neurospora circadian clock. Mol Cell (2009) 1.80
Structure-activity relationship study of novel necroptosis inhibitors. Bioorg Med Chem Lett (2005) 1.72
INF2 is an endoplasmic reticulum-associated formin protein. J Cell Sci (2009) 1.67
Inhibition of bone morphogenetic protein signaling attenuates anemia associated with inflammation. Blood (2011) 1.61
Comparison of human fetal liver, umbilical cord blood, and adult blood hematopoietic stem cell engraftment in NOD-scid/gammac-/-, Balb/c-Rag1-/-gammac-/-, and C.B-17-scid/bg immunodeficient mice. Hum Immunol (2009) 1.53
Characterization of mouse spleen cells by subtractive proteomics. Mol Cell Proteomics (2005) 1.51
Myc protein is stabilized by suppression of a novel E3 ligase complex in cancer cells. Genes Dev (2010) 1.46
MMFPh: a maximal motif finder for phosphoproteomics datasets. Bioinformatics (2012) 1.44
Rapid and reproducible single-stage phosphopeptide enrichment of complex peptide mixtures: application to general and phosphotyrosine-specific phosphoproteomics experiments. Anal Chem (2011) 1.40
Structure-activity relationship study of novel tissue transglutaminase inhibitors. Bioorg Med Chem Lett (2005) 1.38
Budding yeast silencing complexes and regulation of Sir2 activity by protein-protein interactions. Mol Cell Biol (2004) 1.37
A new class of small molecule inhibitor of BMP signaling. PLoS One (2013) 1.36
The structural basis of Cryptosporidium -specific IMP dehydrogenase inhibitor selectivity. J Am Chem Soc (2010) 1.35
Designed inhibitors of insulin-degrading enzyme regulate the catabolism and activity of insulin. PLoS One (2010) 1.35
Absolute quantification of protein and post-translational modification abundance with stable isotope-labeled synthetic peptides. Nat Protoc (2011) 1.34
Triazole inhibitors of Cryptosporidium parvum inosine 5'-monophosphate dehydrogenase. J Med Chem (2009) 1.33
The majority of the Saccharomyces cerevisiae septin complexes do not exchange guanine nucleotides. J Biol Chem (2003) 1.29
Structure-activity relationship study of tricyclic necroptosis inhibitors. J Med Chem (2007) 1.27
Carboetomidate: a pyrrole analog of etomidate designed not to suppress adrenocortical function. Anesthesiology (2010) 1.27
Kinetic mechanistic studies of wild-type leucine-rich repeat kinase 2: characterization of the kinase and GTPase activities. Biochemistry (2010) 1.17
Identification of translational activators of glial glutamate transporter EAAT2 through cell-based high-throughput screening: an approach to prevent excitotoxicity. J Biomol Screen (2010) 1.14
Identification of small molecule inhibitors of the mitotic kinase haspin by high-throughput screening using a homogeneous time-resolved fluorescence resonance energy transfer assay. J Biomol Screen (2008) 1.13
Proteomic analysis shows synthetic oleanane triterpenoid binds to mTOR. PLoS One (2011) 1.13
Omental immune aggregates and tumor metastasis within the peritoneal cavity. Immunol Res (2009) 1.11
Imaging of vascular development in early mouse decidua and its association with leukocytes and trophoblasts. Biol Reprod (2012) 1.11
Small molecules that enhance the catalytic efficiency of HLA-DM. J Immunol (2006) 1.10
Plk1 regulates the kinesin-13 protein Kif2b to promote faithful chromosome segregation. Mol Biol Cell (2012) 1.10
Structure guided design of potent and selective ponatinib-based hybrid inhibitors for RIPK1. Cell Rep (2015) 1.09
Optimization of benzoxazole-based inhibitors of Cryptosporidium parvum inosine 5'-monophosphate dehydrogenase. J Med Chem (2013) 1.09
Insulin-stimulated GLUT4 protein translocation in adipocytes requires the Rab10 guanine nucleotide exchange factor Dennd4C. J Biol Chem (2011) 1.07
Transcriptional interference among the murine beta-like globin genes. Blood (2006) 1.06
Small-molecule activator of glutamate transporter EAAT2 translation provides neuroprotection. J Clin Invest (2014) 1.06
Structures of Down syndrome kinases, DYRKs, reveal mechanisms of kinase activation and substrate recognition. Structure (2013) 1.03
Small-molecule activators of insulin-degrading enzyme discovered through high-throughput compound screening. PLoS One (2009) 1.03
Validation of IMP dehydrogenase inhibitors in a mouse model of cryptosporidiosis. Antimicrob Agents Chemother (2013) 1.03
In vivo and in vitro pharmacological studies of methoxycarbonyl-carboetomidate. Anesth Analg (2011) 1.01
Rapid determination of multiple linear kinase substrate motifs by mass spectrometry. Chem Biol (2012) 1.01
Selective and potent urea inhibitors of cryptosporidium parvum inosine 5'-monophosphate dehydrogenase. J Med Chem (2012) 1.01
MacroSEQUEST: efficient candidate-centric searching and high-resolution correlation analysis for large-scale proteomics data sets. Anal Chem (2010) 1.01
Structure-activity relationship study of selective benzimidazole-based inhibitors of Cryptosporidium parvum IMPDH. Bioorg Med Chem Lett (2012) 1.00
Small-molecule inhibitors of USP1 target ID1 degradation in leukemic cells. Mol Cancer Ther (2013) 0.99
Kinetic studies of Cdk5/p25 kinase: phosphorylation of tau and complex inhibition by two prototype inhibitors. Biochemistry (2008) 0.99
Development of an ALK2-biased BMP type I receptor kinase inhibitor. ACS Chem Biol (2013) 0.99
Defining Cdk5 ligand chemical space with small molecule inhibitors of tau phosphorylation. Chem Biol (2005) 0.98
Yeast Chfr homologs retard cell cycle at G1 and G2/M via Ubc4 and Ubc13/Mms2-dependent ubiquitination. Cell Cycle (2007) 0.97
Biological properties of novel antistaphylococcal quinoline-indole agents. Antimicrob Agents Chemother (2003) 0.97
Identification of tau stem loop RNA stabilizers. J Biomol Screen (2007) 0.97
Exposure to ionizing radiation induces the migration of cutaneous dendritic cells by a CCR7-dependent mechanism. J Immunol (2012) 0.97
Development of improved inhibitors of wall teichoic acid biosynthesis with potent activity against Staphylococcus aureus. Bioorg Med Chem Lett (2010) 0.97
Type I interferons induced by radiation therapy mediate recruitment and effector function of CD8(+) T cells. Cancer Immunol Immunother (2013) 0.96
Structure-activity relationship study of acridine analogs as haspin and DYRK2 kinase inhibitors. Bioorg Med Chem Lett (2010) 0.96
Structure-activity relationship study of [1,2,3]thiadiazole necroptosis inhibitors. Bioorg Med Chem Lett (2007) 0.96
Identification of novel small molecules that elevate Klotho expression. Biochem J (2012) 0.95
The Tlo proteins are stoichiometric components of Candida albicans mediator anchored via the Med3 subunit. Eukaryot Cell (2012) 0.95
Structure-activity relationship study of pyridazine derivatives as glutamate transporter EAAT2 activators. Bioorg Med Chem Lett (2011) 0.95
Genetic ablation or chemical inhibition of phosphatidylcholine transfer protein attenuates diet-induced hepatic glucose production. Hepatology (2011) 0.94
Phthalazinone inhibitors of inosine-5'-monophosphate dehydrogenase from Cryptosporidium parvum. Bioorg Med Chem Lett (2012) 0.94
A high-throughput drug screen targeted to the 5'untranslated region of Alzheimer amyloid precursor protein mRNA. J Biomol Screen (2006) 0.93
Optogenetic control of chemokine receptor signal and T-cell migration. Proc Natl Acad Sci U S A (2014) 0.93
In vivo enhancement of peptide display by MHC class II molecules with small molecule catalysts of peptide exchange. J Immunol (2009) 0.93
FDA-preapproved drugs targeted to the translational regulation and processing of the amyloid precursor protein. J Mol Neurosci (2004) 0.92
A new means to identify type 3 secreted effectors: functionally interchangeable class IB chaperones recognize a conserved sequence. MBio (2012) 0.91
Synthesis, in vitro evaluation and cocrystal structure of 4-oxo-[1]benzopyrano[4,3-c]pyrazole Cryptosporidium parvum inosine 5'-monophosphate dehydrogenase (CpIMPDH) inhibitors. J Med Chem (2014) 0.91
Multisite phosphorylation of the guanine nucleotide exchange factor Cdc24 during yeast cell polarization. PLoS One (2009) 0.90
G-protein-coupled receptor-2-interacting protein-1 is required for endothelial cell directional migration and tumor angiogenesis via cortactin-dependent lamellipodia formation. Arterioscler Thromb Vasc Biol (2013) 0.90
Automatic stent detection in intravascular OCT images using bagged decision trees. Biomed Opt Express (2012) 0.89
Small-molecule Klotho enhancers as novel treatment of neurodegeneration. Future Med Chem (2012) 0.89